Dare Bioscience, INC 8-K filings

Dare Bioscience releases a corporate presentation on January 13, 2025, to be used in meetings with securities market participants and available on their website.

Dare Bioscience has announced plans for a Phase 3 clinical trial of Sildenafil Cream for the treatment of female sexual arousal disorder (FSAD), following discussions with the FDA.

Dar Bioscience announced its third quarter 2024 financial results and provided updates on its clinical development programs, including progress on Ovaprene, Sildenafil Cream, and other pipeline candidates.

Dare Bioscience has released a corporate presentation to be used in meetings with investors and analysts starting October 25, 2024.

Dare Bioscience has been awarded $10 million by ARPA-H to advance its DARE-HPV program, a potential first-in-category treatment for HPV-related cervical diseases.

Dare Bioscience has entered into a $15 million stock purchase agreement with Lincoln Park Capital, providing the company with flexible access to capital.

Dar Bioscience announced its second quarter 2024 financial results, highlighting a significant royalty monetization and continued progress in its clinical development programs.

Dare Bioscience has successfully regained compliance with Nasdaq's minimum bid price requirement after its stock price closed above $1.00 for ten consecutive trading sessions.

Dar Bioscience has enacted a 1-for-12 reverse stock split to increase its share price and regain compliance with Nasdaq's minimum bid price requirement.

Dare Bioscience held its annual meeting on June 5, 2024, where stockholders elected directors, ratified the accounting firm, approved executive compensation, and authorized a potential reverse stock split.

Dar Bioscience announced its first quarter 2024 financial results, highlighting progress in its clinical programs and securing $22 million in non-dilutive financing.

Dare Bioscience has secured $22 million in non-dilutive financing through a royalty monetization agreement with XOMA to advance its Phase 3 women's health product candidates.

Dare Bioscience announced its 2023 financial results and provided a company update, highlighting progress with its late-stage candidates and on-market product, XACIATO.

Dare Bioscience is undergoing a significant restructuring, including the retirement of its CFO, resignation of its CCO, and a reduction in the size of its Board of Directors, all aimed at streamlining operations and reducing costs.

Dare Bioscience, Inc. has received a delisting notice from Nasdaq after its stock price remained below $1.00 for an extended period, and the company plans to appeal the decision.